Abstract | BACKGROUND: METHODS: All the patients received first 24 mg/d of aripiprazole for 3 weeks and later received 6 mg/d of haloperidol for 2 weeks. Blood samplings were performed at least 2 weeks after the initiation of each treatment. The Css values of aripiprazole and dehydroaripiprazole were measured using liquid chromatography with mass spectrometric detection, and those of haloperidol were measured by using an enzyme immunoassay. CYP2D6 genotypes were determined by using polymerase chain reaction analysis. RESULTS: None of the correlations between the Css of aripiprazole (r = 0.286) or the sum of aripiprazole plus dehydroaripiprazole (r = 0.344) and those of haloperidol were significant. The mean Css of aripiprazole was significantly higher (P < 0.05) in the subjects with 1 *10 allele of CYP2D6 (n = 6) than in those with no mutated alleles (n = 13), whereas there were no significant differences in those of haloperidol between the 2 groups. CONCLUSIONS:
|
Authors | Akifumi Nakamura, Kazuo Mihara, Kenji Nemoto, Goyo Nagai, Shoko Kagawa, Takeshi Suzuki, Tsuyoshi Kondo |
Journal | Therapeutic drug monitoring
(Ther Drug Monit)
Vol. 36
Issue 6
Pg. 815-8
(Dec 2014)
ISSN: 1536-3694 [Electronic] United States |
PMID | 24739668
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Piperazines
- Quinolones
- Aripiprazole
- Haloperidol
|
Topics |
- Adult
- Antipsychotic Agents
(blood, therapeutic use)
- Aripiprazole
- Asian People
(genetics)
- Female
- Haloperidol
(blood, therapeutic use)
- Humans
- Male
- Middle Aged
- Piperazines
(blood, therapeutic use)
- Quinolones
(blood, therapeutic use)
- Schizophrenia
(blood, drug therapy, genetics)
|